TITLE

PROMICS GRANTED AUSTRALIAN PATENT FOR ANTI-INFLAMMATORY DRUG

PUB. DATE
October 2002
SOURCE
Worldwide Biotech;Oct2002, Vol. 14 Issue 10, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces that the Australian Patents Office has granted Promics Pty. Ltd. a patent for its anti-inflammatory drug, PMX-53.
ACCESSION #
7464124

 

Related Articles

  • Industry reacts positively to Clinton comments on Medicare drug coverage.  // Medical Marketing & Media;Mar2000, Vol. 35 Issue 3, p18 

    Reports on United States President Bill Clinton's comments on Medicare drug coverage during his state of the nation address. Concerns over government administration of the benefit; Proposal for private sector management; Clinton's complaints against drug prices.

  • Giving drug makers a break. Chase, Stephen // Alberta Report / Newsmagazine;1/11/93, Vol. 20 Issue 4, p11 

    Examines the Bill C-91, which will end Canada's drug war on Parliament Hill over the issue of patent protection. What the bill will provide; Strengthened patent protection; Legislation's bitter fight in Ottawa; What it means for generic drug makers; History of drug-making industry; Benefits for...

  • Quick drug approval. Spencer, P.L. // Consumers' Research Magazine;Jan1992, Vol. 75 Issue 1, p6 

    Reports briefly on several significant events for consumers in Washington. Food and Drug Administration (FDA) plans to get prescription drug approval-process to market sooner; Department of Transportation wants to allow airports to charge airlines higher fees for landing during congested hours;...

  • Good news for Tar Heel pharmacists.  // Drug Topics;8/2/93, Vol. 137 Issue 15, p6 

    Reports on the passage of two bills supported by North Carolina pharmacists. Right of consumers to select pharmacy of their choice; Registration with the state board of pharmacy of mail-order pharmacies that distribute drugs to residents in the state.

  • Untitled. Conlan, Michael F. // Drug Topics;8/2/93, Vol. 137 Issue 15, p80 

    Reports on the development in the pharmaceutical industry. DEA's lobby in Congress for power to tighten regulations over Schedule III Controlled Substance drugs; Federal government's methodical five-year probe of the generic drug industry; Deadline of application for new Medicare supplier...

  • What to do when things go wrong.  // Environmental Nutrition;Oct96, Vol. 19 Issue 10, p3 

    Reports that the MEDWatch program of the Food and Drug Administration gives assistance to consumers who experience adverse effects from medications. Possible product recalls after analysis of situation; Contact information.

  • Speeding help and hope to the desperately ill. Young, F.E. // FDA Consumer;Feb1989, Vol. 23 Issue 1, p8 

    Explains the US Food and Drug Administration's (FDA) most recent steps to reduce the time needed to test new drugs for life-threatening diseases, (such as acquired immune deficiency syndrome and cancer), and diseases that cause permanent disability. Ensuring proper safeguards for safety and...

  • Putting pressure on illegal steroid traffic. Modeland, V. // FDA Consumer;Oct89, Vol. 23 Issue 8, p33 

    Reports on recent US law enforcement agency investigation, indictments and prosecutions under the Anti-Drug Abuse Act of 1988. This Act prohibits distribution of anabolic steroids, a synthetic derivative of testosterone, for any use other than treatment of a disease under a physician's orders.

  • Speedier approval rules.  // FDA Consumer;Mar1993, Vol. 27 Issue 2, p5 

    Reports that final rules to speed the approval of drugs and biologics for people with serious or life-threatening diseases, such as cancer, AIDS, or Alzheimer's disease, went into effect on Jan. 11, 1993. Regulations published in the Dec. 11, 1992 issue of the `Federal Register'; Benefits of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics